Anixa Biosciences Inc Stock Price, News & Analysis

Anixa Biosciences (NASDAQ: ANIX) has completed dosing the final patient in the third cohort of its Phase 1 clinical trial for a novel CAR-T therapy targeting recurrent ovarian cancer, conducted in partnership with Moffitt Cancer Center. The third cohort received one million CAR-positive cells per kilogram, a tenfold increase from the first cohort.

The trial's fourth cohort is set to begin after a 30-day safety verification period, with plans to increase dosage by another factor of three. The therapy targets the follicle-stimulating hormone receptor (FSHR), which is exclusively expressed on ovarian cells, tumor vasculature, and certain cancer cells.

A recent protocol amendment allows eligible patients to receive a second dose if beneficial and expands enrollment criteria to include rare ovarian cancer subtypes. The first-in-human trial (NCT05316129) focuses on adult women with recurrent ovarian cancer who have progressed after at least two prior therapies, evaluating safety, maximum tolerated dose, and efficacy.

Anixa Biosciences' breast cancer vaccine was featured on Fox News' "America Reports," highlighting its potential to revolutionize breast cancer prevention by targeting the disease at its earliest stages. The vaccine trains the immune system to recognize α-lactalbumin, a protein expressed during lactation and in breast cancer cells, potentially providing preemptive protection against emerging tumors.

The ongoing Phase I clinical trial, conducted with Cleveland Clinic and funded by the U.S. Department of Defense, shows promising progress with a strong safety profile. The vaccine has been well tolerated, with protocol-defined immune responses observed in over 70% of patients. A Phase 2 study in the neoadjuvant setting is planned to begin in 2025.

Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, expressed optimism about the vaccine's potential impact in reducing the incidence of triple-negative breast cancer and other breast cancers.

Anixa Biosciences (NASDAQ: ANIX) announced that its CAR-T therapy for ovarian cancer, developed with Moffitt Cancer Center, was featured in Breaking Cancer News. The therapy, exclusively licensed from The Wistar Institute, targets the follicle-stimulating hormone receptor (FSHR) protein found on ovarian cancer cells.

The clinical trial is being led by Dr. Robert Wenham and Dr. Monica Avila from Moffitt Cancer Center. This innovative approach aims to revolutionize ovarian cancer treatment by using the body's immune system to attack tumors directly. The article discusses potential study expansion to evaluate repeat dosing and explores broader implications for CAR-T therapy in solid tumors.

Anixa Biosciences (NASDAQ: ANIX) and Moffitt Cancer Center have received approval for a protocol amendment in their ongoing ovarian cancer CAR-T therapy clinical trial. The amendment brings two significant changes: it allows eligible patients to receive a second dose of CAR-T therapy without requiring individual IND approvals, and expands enrollment eligibility to include patients with sex cord-stromal tumors (SCSTs) and Sertoli Leydig cell tumors (SLCTs).

Previously, Anixa and Moffitt had secured a single patient IND approval for an additional dose for a patient whose biopsy showed cellular infiltration and necrosis, indicating biological activity of the CAR-T therapy. The amendment aims to optimize treatment outcomes for patients with ovarian cancer by providing more flexibility in dosing and expanding the types of ovarian cancers that can be treated.

Anixa Biosciences (NASDAQ: ANIX) CEO Dr. Amit Kumar discussed the company's innovative cancer treatments in an Alpha Wolf Trading interview. The company is developing two main programs: a CAR-T cell therapy for ovarian cancer and a breast cancer vaccine.

The CAR-T therapy aims to overcome challenges in treating solid tumors, distinguishing it from traditional approaches that work primarily on blood cancers. The breast cancer vaccine targets triple-negative breast cancer (TNBC), the most aggressive form of the disease.

The company emphasizes its capital-efficient business model, maintaining a low burn rate through strategic partnerships with research institutions. This approach reduces the need for extensive in-house R&D expenditures while advancing their therapeutic developments.

Anixa Biosciences (NASDAQ: ANIX) has announced its participation in the 18th Annual European Life Sciences CEO Forum, scheduled for February 26-27, 2025, at the Hilton Zurich Airport Hotel in Switzerland. Mike Catelani, President and CFO, will present on February 27 at 10:40 AM CET.

The presentation will focus on Anixa's pipeline updates, including their:

• CAR-T therapy for ovarian cancer (collaboration with Moffitt Cancer Center)
• Breast cancer vaccine (partnership with Cleveland Clinic)
• Expanding portfolio of cancer vaccine programs

The conference brings together key executives, investors, and industry experts from the global life sciences sector to discuss innovations, investment trends, and partnership opportunities. Mr. Catelani will also conduct one-on-one meetings with potential partners and investors to discuss strategic initiatives and clinical advancements in their innovative therapies.

Anixa Biosciences (NASDAQ: ANIX) CEO Dr. Amit Kumar appeared on CW39's H-Town Live to discuss the company's innovative approach to breast cancer prevention. The segment highlighted Anixa's collaboration with the Cleveland Clinic in developing a novel vaccine targeting triple-negative breast cancer (TNBC), the most aggressive form of the disease.

The vaccine, currently in clinical trials, is designed to target a specific protein present in TNBC cells but absent in normal breast tissue. The goal is to stimulate the immune system to eliminate cancer cells before they develop into tumors, potentially eliminating the need for traditional treatments like chemotherapy and surgery.

Anixa Biosciences (NASDAQ: ANIX) reported significant progress in 2024, maintaining strong financials with $20 million in cash and investments after using only $7 million during the fiscal year. The company presented positive preliminary Phase 1 data for their breast cancer vaccine at SITC, showing protocol-defined immune responses in over 70% of patients across three groups: recurrence, prevention, and therapeutic.

Their CAR-T program for ovarian cancer progressed through the second dose cohort and began the third, with one patient from the first cohort showing strong response and surviving 21+ months post-treatment. The company expanded their vaccine development to include prostate, lung, and colon cancers.

For 2025, Anixa plans to complete the breast cancer vaccine Phase 1 trial and initiate Phase 2, complete treatment of third through fifth dose cohorts in the CAR-T trial, and continue developing vaccines for multiple cancer types. With a 2.5-year cash runway and debt-free structure, the company is positioned to execute its development plans.

Anixa Biosciences (NASDAQ: ANIX), a biotechnology company specializing in cancer treatment and prevention, has announced its participation in the iAccess Alpha Virtual Best Ideas Winter Conference 2024. The event will take place on December 10th and 11th, 2024.

Dr. Amit Kumar, CEO of Anixa, will deliver a presentation on Tuesday, December 10th at 2:00 p.m. EST. The company's management team will be available for one-on-one meetings with qualified investors on Wednesday, December 11th.

The conference, hosted by iAccess Alpha, features companies recommended by an investor network and follows a two-day format with company webcasts on the first day and one-on-one management meetings on the second day.